Clinical Trial Update: Safety and Efficacy of SCT200 in Patients With Relapsed or Metastatic Triple Receptor Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating SCT200 for safety and efficacy in relapsed or metastatic triple receptor negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• SCT200

Snippet

Sponsor: Sinocelltech Ltd. | Conditions: Triple Negative Breast Neoplasms | Phase 2 | Status: UNKNOWN